Ulrika Wählby Hamrén - Clinical Pharmacology & Quantitative Pharmacology, R&D, AstraZeneca, Gothenburg, Sweden.

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 28 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Safety and Pharmacokinetics of Nirsevimab in Immunocompromised Children

Joseph Domachowske,Ulrika Wählby Hamrén, Irfana Banu, Roberta Baronio, Bhanu Basavaraju,Anthonet Koen,Amanda Leach,Vaishali S Mankad,Pia S Pannaraj, Pere Soler-Palacin,Therese Takas, Masaaki Mori,Tonya Villafana, MUSIC Study Group

Pediatricsno. 4 (2024)

引用0浏览0WOS引用

Molecular and Phenotypic Characteristics of RSV Infections in Infants During Two Nirsevimab Randomized Clinical Trials

Bahar Ahani,Kevin M. Tuffy,Anastasia A. Aksyuk,Deidre Wilkins,Michael E. Abram,Ron Dagan,Joseph B. Domachowske,Johnathan D. Guest, Hong Ji,Anna Kushnir,Amanda Leach,Shabir A. Madhi,Vaishali S. Mankad,Eric A. F. Simoes, Benjamin Sparklin,Scott D. Speer,Ann Marie Stanley,David E. Tabor,Ulrika Wahlby Hamren,Elizabeth J. Kelly,Tonya Villafana

Nature communicationsno. 1 (2024)

引用2浏览0WOSNATURE引用

Population Pharmacokinetics of Nirsevimab in Preterm and Term Infants

Lindsay Clegg,Ed Freshwater,Amanda Leach,Tonya Villafana,Ulrika Waehlby Hamren

JOURNAL OF CLINICAL PHARMACOLOGYno. 5 (2024): 555-567

引用0浏览0WOS引用

Molecular and Phenotypic Characteristics of Respiratory Syncytial Virus Isolates Recovered from Medically Vulnerable Children: an Exploratory Analysis of a Phase 2/3 Randomized, Double-Blind, Palivizumab-Controlled Trial of Nirsevimab (MEDLEY)

Kevin M. Tuffy,Bahar Ahani,Joseph B. Domachowske,Kenji Furuno, Hong Ji,Shabir A. Madhi,Vaishali S. Mankad,Ulrika Wahlby Hamren,Tonya Villafana, Yingyi Wang,Elizabeth J. Kelly,Deidre Wilkins

VACCINEno. 24 (2024)

引用0浏览0WOS引用

Comprehensive Summary of Safety Data on Nirsevimab in Infants and Children from All Pivotal Randomized Clinical Trials

Vaishali S. Mankad,Amanda Leach,Yue Chang,Ulrika Waehlby Hamren,Alexandre Kiazand,Robert J. Kubiak,Therese Takas,Tonya Villafana,Manish Shroff

Pathogensno. 6 (2024): 503-503

引用0浏览0WOS引用

Durability of Neutralizing RSV Antibodies Following Nirsevimab Administration and Elicitation of the Natural Immune Response to RSV Infection in Infants

Deidre Wilkins,Yuan,Yue Chang,Anastasia A. Aksyuk,Beatriz Seoane Núñez,Ulrika Wählby-Hamrén,Tianhui Zhang,Michael E. Abram,Amanda Leach,Tonya Villafana,Mark T. Esser

Nature Medicineno. 5 (2023): 1172-1179

引用6浏览0WOSNATURE引用

Safety, Tolerability, and Pharmacokinetics of Nirsevimab for the Prevention of RSV Disease in Immunocompromised Children Aged ≤24 Months: Music, an Open Label, Phase 2 Trial

Joseph B Domachowske,Ulrika Wählby Hamren, Bhanu Basavaraju,Anthonet Koen,Amanda Leach,Vaishali S Mankad,Masaaki Mori, Carl Ndibmun,Pere Soler-Palacin,Pia S Pannaraj,Therese Takas,Tonya Villafana

Blood (2023): 1173

引用0浏览0引用

Efficacy of Nirsevimab Against Respiratory Syncytial Virus Lower Respiratory Tract Infections in Preterm and Term Infants, and Pharmacokinetic Extrapolation to Infants with Congenital Heart Disease and Chronic Lung Disease: a Pooled Analysis of Randomised Controlled Trials

Eric A. F. Simoes,Shabir A. Madhi,William J. Muller,Victoria Atanasova,Miroslava Bosheva,Fernando Cabanas,Manuel Baca Cots,Joseph B. Domachowske,Maria L. Garcia-Garcia, Ineta Grantina,Kim A. Nguyen,Heather J. Zar,Anna Berglind, Celeste Cummings,M. Pamela Griffin,Therese Takas, Yuan,Ulrika Waehlby Hamrin,Amanda Leach,Tonya Villafana

LANCET CHILD & ADOLESCENT HEALTHno. 3 (2023): 180-189

引用42浏览0WOS引用

1934. Nirsevimab is Associated with Higher and More Sustained RSV Neutralizing Antibody Responses Compared with Standard of Care Palivizumab: Observations from a 2:1 Randomized, Phase 2/3 Trial in Medically Vulnerable Children (MEDLEY)

Deidre Wilkins,Ulrika Wählby Hamrén,Yue Chang,Joseph B. Domachowske,Janet A. Englund,William J. Muller, Amanda Leach,Tonya Villafana,Elizabeth J. Kelly

Open forum infectious diseasesno. Supplement_2 (2023)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn